Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

    ... Lenalidomide leads to high rates of erythroid transfusion independence ... parameters and TP53 mutations. These data also indicate that lenalidomide per se is not leukemogenic. Length of treatment can be tailored ...

    Research Article last updated 11/05/2012 - 9:37am.

  2. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine each have activity in ... therapy with azacitidine (75mg/m(2)/d x 5 days) and lenalidomide (10mg/d x 21 days (28-day cycle)) in patients with higher-risk ...

    Research Article last updated 10/01/2012 - 9:58am.

  3. Clinical Trial Basics

    ... (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) eculizumab (Soliris) ...

    Page last updated 03/29/2016 - 7:29pm.

  4. Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?

    ... Currently, combination therapies of azacitidine with lenalidomide appear to be promising thus making them an appealing option ...

    Research Article last updated 06/20/2013 - 11:05am.

  5. Benjamin L. Ebert, MD, PhD

    ... Recent work has elucidated the mechanism of action of lenalidomide , a drug that acts by modulating the function of an ...

    Bio last updated 03/11/2016 - 1:41pm.

  6. Alan List, MD

    ... (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which ...

    Bio last updated 03/11/2016 - 1:41pm.

  7. What are the treatments for MDS?

    ... of healthy bone marrow cells. These therapies include lenalidomide (Revlimid), decitaibine (Dacogen) and azacitidine ...

    FAQ last updated 03/15/2016 - 11:31pm.

  8. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... Lenalidomide (LEN) has been shown to yield red blood cell (RBC) ...

    Research Article last updated 04/24/2012 - 2:47pm.

  9. Therapies

    ... low- and high-risk patients with all sub-types of MDS. Lenalidomide (Revlimid®) is approved for transfusion-dependent MDS ...

    Page last updated 03/18/2016 - 11:26am.

  10. Amer Zeidan, M.D.

    ... and his colleagues confirmed the clinical benefits of lenalidomide and iron chelation therapy in patients with MDS at the ...

    Bio last updated 03/11/2016 - 1:41pm.